FGFR2 and cholangiocarcinoma: Pemigatinib, infigratinib, and futibatinib have been approved by the US Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement.